ArticleNeuro-oncology practice2025
Presenting clinical and radiographic features of diffuse glioma molecular subtypes in accordance with the 2021 CNS5 WHO classification.
Article in Neuro-oncology practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Habitat subregions analysis based on neurite orientation dispersion and density imaging enhances isocitrate dehydrogenase genotyping in glioma.BMC medical imaging · 2025Article
- Epidemiology of WHO grade 2 and grade 3 gliomas from 2009 to 2021 in Germany.Journal of neuro-oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The incorporation of molecular parameters into WHO CNS5 has led to reclassification of gliomas. We describe presenting clinical and radiographic features of diffuse adult gliomas according to CNS5 category. Methods: We reviewed pathology reports, clinical and MRI data at presentation of 972 adult patients with glioma between January 2010 and February 2022. Continuous variables were presented as median; categorical variables as numbers and percentages. Comparison was performed using Fisher's exact test. Results: Seven hundred and thirty-six patients had sufficient data for CNS5 reclassification: Grade 2 IDH mutant (IDHmut) astrocytoma (A2) Conclusion: Significant differences in the clinical and radiographic features exist among CNS5 glioma subtypes, informing potential diagnosis, management and prognosis at initial presentation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.